Anti-TL1A Antibody Dosing Guided by TNFSF15 Haplotype Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, often result in non-response or loss of response, and there is a need for effective, safe, and well-tolerated therapies that can drive gastrointestinal healing and be guided by biomarkers.
Innovation Solution
A method involving genotyping to determine patient haplotype B carrier status for TNFSF15 SNPs (rs3810936, rs6478108, rs6478109, rs7848647, and rs7869487) to identify non-responsive patients, followed by administration of an anti-TNF-like ligand 1A (TL1A) antibody in specific dosing regimens to treat IBD, particularly ulcerative colitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current biologic therapies (anti-TNF, anti-integrin, anti-IL-12/23) are used to treat IBD, then immune cell activation is targeted, but non-response and loss of response occur in many patients
Solution Approach 1:
The patent introduces a fundamentally new therapeutic target (TL1A) with different mechanistic parameters compared to existing biologics. Anti-TL1A antibodies block a distinct cytokine pathway (TL1A-DR3 interaction) rather than targeting TNF, integrins, or IL-12/23, thereby changing the therapeutic parameter space and offering efficacy to patients who fail conventional therapies
2Measurement precision
If genotyping assays are performed to determine haplotype B carrier status, then patient stratification for treatment selection is achieved, but additional testing time and complexity are required
Solution Approach 1:
The patent performs genotyping assays for TNFSF15 haplotype B status before initiating anti-TL1A antibody treatment. This preliminary genetic characterization identifies patients most likely to respond (haplotype B non-carriers), enabling proactive treatment selection and avoiding futile therapy in haplotype B carriers
Data Source
AI summary
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.